We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $186M
1-Year Est. Return 155.23%
This Fund
S&P 500
This Quarter Est. Return
-30.64%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$135M
AUM Growth
-$76.5M
Cap. Flow
-$1.17M
Cap. Flow %
-0.87%
Top 10 Hldgs %
96.04%
Holding
14
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$15

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$740K
2
KZR
Kezar Life Sciences
KZR
+$431K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$1.36B
$51M 37.84%
5,103,455
– –
TBIO
2
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$18.3M 13.55%
2,437,603
+2
+0% +$15
KZR
3
DELISTED
Kezar Life Sciences
KZR
$15.9M 11.82%
67,562
-1,765
-3% -$431K
PRTK
4
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13.3M 9.89%
2,600,410
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$12.7M 9.38%
999,364
– –
KYNB
6
Kyntra Bio
KYNB
$32.6M
$6.05M 4.48%
5,226
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$4.34M 3.22%
551,477
– –
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$3.55M 2.63%
75,440
– –
EPIX
9
DELISTED
ESSA Pharma
EPIX
$2.28M 1.69%
1,084,848
– –
PVLA
10
Palvella Therapeutics
PVLA
$2.18B
$2.07M 1.53%
9,728
– –
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.79M 1.32%
167,157
-56,300
-25% -$740K
JNCE
12
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.79M 1.32%
529,965
– –
SNNA
13
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$1.76M 1.3%
758,610
– –
EGLT
14
DELISTED
Egalet Corporation
EGLT
$7K 0.01%
2,889,926
– –

Similar funds

LBC
Leigh Baldwin & Co Cazenovia, New York $186M AUM 40.09% 1-Year Est. Return
GWCM
Godshalk Welsh Capital Management Radnor, Pennsylvania $186M AUM 18.63% 1-Year Est. Return
FWM
Fingerlakes Wealth Management Ithaca, New York $186M AUM 30.5% 1-Year Est. Return
LOIP
Live Oak Investment Partners Austin, Texas $186M AUM 19.39% 1-Year Est. Return
TFA
Tranquilli Financial Advisor Clinton, New Jersey $186M AUM 18.12% 1-Year Est. Return
NCM
Northland Capital Management Virginia, Minnesota $186M AUM 16.43% 1-Year Est. Return
GPI
General Partner Inc Pittsburgh, Pennsylvania $186M AUM 25.15% 1-Year Est. Return
MWM
Melfa Wealth Management Westborough, Massachusetts $185M AUM 17.73% 1-Year Est. Return

Omega Fund Management's Q4 2018 Portfolio in Review

As of Q4 2018, Omega Fund Management held 14 positions worth $135M, down 36% from $211M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Trading was light in Q4 2018: portfolio turnover was 0%. Omega Fund Management opened no new positions and made no exits, leaving the 14-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management added most to Translate Bio, Inc. Common Stock in Q4 2018, an estimated $15 increase.
  • Omega Fund Management's biggest Q4 2018 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $740K.
  • Omega Fund Management's ten largest holdings make up 96% of its $135M portfolio in Q4 2018.
  • Omega Fund Management opened 0 new positions and closed 0 in Q4 2018.
  • Omega Fund Management's portfolio value fell 36% quarter-over-quarter to $135M.

Based on Omega Fund Management's 13F filing for Q4 2018, filed 11 Feb 2019.